Acute limb ischemia in COVID-19 patients: an overview

Hashem Bark Abood1*, Wael Hamed Alsaedi2, Abdulwahab Mohammad Bokhari3, Ahmad Mohammed Almughalleq4, Ranin Owaith Algethami5, Sama Mohammed Zaini6, Hanin Abdulrahman Ayoub7, Maan Khaled Baamer3, Wael Hassan Alanazi8, Ahmed Ebraheem Al Mohammedali8, Zoha Saleh Alghamdi9

ABSTRACT

COVID-19 causes a wide range of clinical symptoms. COVID-19 hematologic and cardiovascular involvement induces thromboembolic symptoms in various organs, most notably venous thromboembolism (VTE); peripheral arterial involvement is uncommon. Acute limb ischemia (ALI) is a vascular emergency known as a dramatic drop in arterial perfusion of a limb that poses a challenge to the limb's viability. Given routine need for thromboprophylaxis, hospitalised COVID-19 patients are at an elevated risk of ALI, limb loss, or even mortality. Understanding the various specific symptoms of COVID-19 patients, especially extrapulmonary manifests, is crucial for both better patient care and the development of adequate infection prevention methods. Although ALI is a complication of COVID-19 in hospitalized patients, it is now being understood that it can arise in patients with mild COVID-19 symptoms, and that ALI can be the first presenting sign of COVID-19 even in the absence of respiratory symptoms. It is recommended that acutely admitted COVID-19 cases should be given pharmacologic thromboprophylaxis with low molecular weight heparin (LMWH) or fondaparinux unless there is a chance of bleeding or contraindicated. Anticoagulant treatment, primarily with LMWH, correlates strongly with an improved prognosis in serious COVID-19 patients who follow sepsis-induced coagulopathy requirements or have significantly elevated D-dimer levels.

Keywords: COVID-19, SARS-CoV-2, Ischemia, ALI, Thrombosis

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is caused by extreme acute respiratory syndrome coronavirus 2 and has been declared a global pandemic by the World health organization.1 It is a positive-sense, single-stranded, enveloped RNA virus with a helical capsid.2 Coronavirus disease 2019 (COVID-19) is a multi-systemic infection that mainly affects the respiratory, hematologic, and cardiovascular systems.3 COVID-19 causes a wide range of clinical symptoms, including bilateral pneumonia, acute respiratory distress...
syndrome (ARDS), endothelial dysfunction, hypercoagulability, and multiorgan failure. COVID-19 hematologic and cardiovascular involvement induces thromboembolic phenomena in various organs, most notably venous thromboembolism (VTE); peripheral arterial involvement is uncommon. Klok et al performed a study on 184 COVID-19 patients, finding that the average rate of thrombosis was 31 percent, with venous thromboembolism accounting for 27 percent of cases and arterial thrombotic incidents accounting for 3.7 percent.

The majority of SARS-CoV-2 patients diagnosed with limb ischemia had increased inflammatory markers and were mostly elderly. Furthermore, angiotensin-converting enzyme 2, the SARS-CoV-2 receptor, is expressed on the membrane of vascular muscle and endothelial cells, and infection of these cells can cause an inflammatory response in the blood vessel walls, predisposing to clot developing.

Acute limb ischemia (ALI) is a vascular emergency known as a dramatic drop in arterial perfusion of a limb that poses a challenge to the limb's viability. The most frequent causes involve embolism from cardiac chambers, and is most often combined with atrial fibrillation or acute myocardial infarction, embolism from arterial aneurysms, thrombosis of native limb arteries or artery grafts, iatrogenic thromboembolism after vascular procedures, aortic dissection, and traumatic vascular injury. COVID-19 patients who present with acute lower extremity ischemia caused by arteriosclerosis obliterans and venous thrombosis at the same time have a poor prognosis and a higher mortality rate.

There has been an increase in the prevalence of ALI in COVID-19 patients. COVID-19 patients present with acute lower extremity ischemia due to arteriosclerosis obliterans and venous thrombosis at the same time have a worse prognosis and a higher mortality rate. The prevalence of ALI correlated with COVID-19 patients that need hospitalisation varies from 3% to 15%

**CURRENT BURDEN**

Evolving findings of vascular skin results in COVID-19 patients increase the risk infection could present with the sequelae of a virally induced hypercoagulable state, possibly accompanying or in the absence of concomitant respiratory symptoms. Infection can also reveal a hypercoagulable condition in patients with pre-existing risk factors such as diabetes, which leads to endothelial dysfunction and increased platelet activation. In Saudi Arabia, a study at King Abdullah university hospital (KAUH) involved 1300 COVID-19 patients; 0.54% of patients had acute lower limb ischemia (ALLI). (28.57%) of had asymptomatic COVID-19 infection and (71.43%) of them developed ALLI during their admission due to COVID-19.

Furthermore, the study’s results revealed an improvement in ALLI among COVID-19 patients in ICUs (two cases in the last year compared to five cases in two months). A retrospective research was undertaken in Italy to investigate the prevalence and outcomes of 20 patients with acute limb ischemia. According to the results, the rate of acute limb ischemia was higher in the first few months of 2020 compared to 2019, and the higher incidence was attributed to an increase in cases triggered by thromboembolic disease associated with COVID-19. Bellosta et al conducted a single-center, retrospective cohort analysis and discovered that the incidence of ALI increased dramatically during the COVID-19 pandemic.

Topcu et al performed a case study and found that COVID-19 infection is associated with increased occurrence of thromboembolic events, such acute limb ischemia (ALI). Also, young and sometimes stable patients will grow ALI despite prophylactic anticoagulation.

Putko et al investigated the prevalence documenting COVID-19 affected patients with limb or digit ischemia; the results of the search support the hypothesis that SARS-CoV-2 infection is associated with an elevated risk of limb ischemia. Although the precise pathophysiology is unclear, evidence for inflammatory-mediated thrombosis is one plausible cause, which may justify the use of immunotherapy in combination with anticoagulation for the treatment and/or prevention of thromboembolic events.

Kartikasari et al published a case report and discovered a connection between COVID-19 infections and coagulopathy, which can occur as acute limb ischemia. This study is intended to improve understanding of hypercoagulation in COVID-19 patients and acute limb ischemia as a potential manifestation.

**PATHOGENESIS**

In SARS-CoV-2 patients, so many researchers noted an inflammatory-mediated thrombosis pathway. To explain this effect, various mechanisms have been suggested. Several authors have identified an inflammatory-mediated thrombosis pathway in SARS-CoV-2 patients. This pro-inflammatory condition is induced not only by inflammatory cytokines that induce a pro-thrombotic state, but it is also suspected that SARS-CoV-2 will directly infect endothelial cells through the alveolar ACE2 receptor, resulting in both endothelial cell activation and dysfunction. The arterial and venous thromboembolic events seen in COVID-19 patients are believed to be the result of a dysregulated hyperinflammatory reaction. COVID-19 patients have consuming coagulopathy, which is close to sepsis-associated disseminated intravascular coagulopathy (DIC).

There is a rise in D-dimer, fibrinogen, coagulation factors, acquired antiphospholipid antibodies,
and a decline in protein C, protein S, antithrombin, and platelet and neutrophil hyperactivation. It is likely that the elevated rate of arterial thromboembolic events in COVID-19 patients is caused by a composite of these pathways, rather than just one.

Furthermore, several studies show that severe COVID-19 infections increase the number of helper T lymphocytes, which contain an abundance of CD14 and CD16; these monocytes then promote the formation of IL-6, a central mediator in COVID-19. IL-6 is a cytokine that stimulates the development of acute-phase reactants (APRs) in the liver, such as CRP and fibrinogen. These two APRs play an important role in making the body hypercoagulable, which contributes to thrombosis. Putko et al found increased inflammatory factors and/or changed clotting parameters in the vast majority of patients. This was true particularly in patients who did not have any major baseline comorbidities.

DISCUSSION

Limb ischemia in SARS-CoV-2 positive patients poses a novel risk to physicians who treat extremity injuries. In the treatment of patients with COVID-19-associated ALI, prompt vascular surgery consultation is important.

Although ALI is a complication of COVID-19 in hospitalized patients, it is now being understood that it can arise in patients with mild COVID-19 symptoms, and that ALI can be the first presenting sign of COVID-19 even in the absence of respiratory symptoms. In a study of 49 patients diagnosed with COVID-19, 22 (45%) showed symptoms of acute arterial ischemia before being diagnosed with COVID-19, while the remaining 27 (55%) experienced ischemia during hospitalization.

Infected patients with little to no COVID-19 symptoms can experience a prothrombotic state, and some studies have identified patients who complained mostly of acute extremity discomfort, which was mostly accompanied by moderate respiratory symptoms or other COVID-19 symptoms, although in some instances, ALI was the only clinical manifestation of COVID-19. ALI has also been recorded after recovering from a mild infection.

Since arterial thrombosis may arise without the typical risk factors for ALI, a high index of suspicion is required to detect developing ALI and provide prompt, targeted care. The diagnosis of ALI is mostly clinical, relying on physical examination findings, such as assessment of extremity pressures, and the patient's medical history. Vascular imaging helps plan surgery by confirming the presence and degree of arterial obstruction.

The most popular confirmatory imaging modalities are duplex ultrasound and CT angiography, which help assess the anatomic site and degree of the arterial occlusion. A proximal thromboembolic origin can be identified using CT angiography. The vascular imaging analysis used in the COVID-19 pandemic was based on the patient's stabilization for transition to the imaging lab, if necessary, as well as concern for resource distribution. Just 8 patients with acute upper or lower extremity ischemia received confirmatory imaging trials in a limited group of 16 patients. In addition, there is normally sufficient time to undergo vascular imaging prior to surgery for patients with viable or partially endangered limbs. Patients that are in imminent danger of losing a limb, on the other hand, need more immediate assessment, usually in an emergency room.

MANAGEMENT INTERVENTIONS

Based on the patient's general health, degree of ischemia, and limb viability, it must be determined if surgery is necessary and, if so, if an endovascular or open solution should be used. When seeking action, it is important to understand the seriousness of systemic disease. Open thrombectomy is the primary surgical revascularization procedure for ALI, while other adjuncts such as endarterectomy/patch angioplasty and/or surgical bypass may be available. Endovascular revascularization can involve catheter-directed thrombolysis or percutaneous mechanical thrombectomy (a variety of devices are obtainable). A combination of open and endovascular approaches may be required in some cases. In one case of ALI caused by severe thrombosis of an aortic aneurysm, iliac arteries, and infragenual arteries, thrombolytic therapy preserved aortoiliac occlusion patency and bilateral open thrombectomy of the infragenual vessels restored distal perfusion.

In addition, all COVID-19 cases admitted to the hospital must be given pharmacologic thromboprophylaxis with low molecular weight heparin (LMWH) or fondaparinux unless there is a chance of bleeding and complete therapeutic-intensity anticoagulation in the right clinical situation. Anticoagulant treatment, primarily with LMWH, correlates strongly with an improved prognosis in serious COVID-19 patients who follow sepsis-induced coagulopathy requirements or have significantly elevated D-dimer levels.

According to Sánchez et al thromboembolectomy was performed using an embolectomy catheter sized according to the location of occlusion. Anticoagulation therapy with low-molecular-weight heparin (LMWH) and UFH during hospitalisation and with LMWH was started for patients as a bridging treatment to warfarin at discharge. An analysis of 449 COVID-19 patients found that those given prophylactic doses of heparin and enoxaparin had a statistically significant reduction in deaths (40.0 percent experimental, 64.2 percent control).

CONCLUSION

COVID-19 is an outbreaking multi-systemic disorder affecting the hematologic and cardiovascular systems. Given routine need for thromboprophylaxis, hospitalized
COVID-19 patients are at an elevated risk of ALI, limb loss, or even mortality. Understanding the various specific symptoms of COVID-19 patients, especially extrapulmonary manifestations, is crucial for both better patient care and the development of adequate infection prevention methods.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: Not required

REFERENCES
